DMD # 65698

TITLE

Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids

Curtis D. Klaassen and Julia Yue Cui

Department of Environmental and Occupational Health Sciences

University of Washington

Seattle, WA 98105
Running Title: Intestinal bacteria and drug metabolism

Send correspondence to:

Curtis D. Klaassen PhD
Address:
2416 112th Street, Leawood KS 66211
Email: curtisklaassenphd@gmail.com
Tel: 913-661-4616

Number of text pages: 64
Tables: 2
Figures: 20
References: 105
Number of words in Abstract: 228
Number of words in Introduction: 304
Number of words in Discussion: 126

Abbreviations:

16S rRNA, 16 subunit ribosomal RNA; 5-FU, 5-fluoruracil; Abc, ATP-binding cassette; AhR, aryl-hydrocarbon receptor; Asbt, apical sodium bile acid transporter; Atp, adenosine tri-phosphate; BA, bile acid; Bcrp, Breast cancer resistant protein; Bsep, bile salt export pump; BSH, bile salt hydrolase; CA, cholic acid; CDCA, chenodeoxycholic acid; CFTR, cystic fibrosis trans-membrane and conductance regulator; cgr, cardiac glycoside reductase; COX, cyclooxygenase; Cut, choline utilization cluster; CutC, choline TMA lyase; Cyp, cytochrome P450; D2, iodothyronine-deiodinase; DNA, deoxyribonucleic acid; E., Eggerthella; Fgf, fibroblast growth factor; Fmo, flavin monoxygenase; GLP-1, glucagon-like peptide-1; Glu-P-1, 2-amino-6-methylpyrido(1,2-a:3',2'-d)imidazole; Glu-P-2, 2-amino-dipyrido(1,2-a:3',2'-d)imidazole; GPCR, G protein-coupled receptor; GPR, G-protein coupled receptor; GRE, glycyl radical enzyme;
H., Helicobacter; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; HPLC-MS/MS, high-pressure liquid chromatography-mass spectrometry/mass spectrometry; HSDH, hydroxysteroid dehydrogenases; IL-22, interleukin-22; IQ, 2-amino-3-methylimidazo[4,5f]quinolone; MCA, muricholic acid; Me1Qx, 2-amino-3,8-dimethylimidazo(4,5)quinoxaline; mRNA, messenger-RNA; NAPQI, N-acetyl-p-benzoquinoneimine; NASH, non-alcoholic steatohepatitis; NSAIDs, non-steroidal anti-inflammatory drugs; Ntcp, sodium taurocholate cotransporting polypeptide; Oatp, organic anion transporting polypeptide; Ost, organic solute transporter; PAPS, 3'-phosphoadenosine-5'-phosphosulfate; PhIP, 2-amino-1-methyl-6-phenylimidazo(4,5b)pyridine; PPARα, peroxisomal proliferator activated receptor; PXR, pregnane X receptor; T3, tri-iodothyronine; T4, tetra-iodothyronine or thyroxine; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDF, tetrachlorodibenzo-furan; TGR5, transmembrane G protein-coupled receptor; TMA, trimethylamine; TMAO, trimethylamine N-oxide; Trp-P-1, 3-amino-1,4-dimethyl-pyrido(4,3-b)indole; Trp-P-2, 1-methyl-3-amino-5H-pyrido(4,3-b)indole; Ucp, uncoupler protein; UDP, uridine-diphospho; uidA, beta-D-glucuronidase.
ABSTRACT

Information on the intestinal microbiota has increased exponentially this century due to technical advancements in genomics and metabolomics. While information on the synthesis of bile acids by the liver and their transformation to secondary bile acids by the intestinal microbiota was the first example of the importance of the intestinal microbiota in biotransforming chemicals, this review will discuss numerous examples of the mechanisms by which the intestinal microbiota alters the pharmacology and toxicology of drugs and other chemicals. More specifically, the altered pharmacology and toxicology of salicylazosulfapridine, digoxin, L-dopa, acetaminophen, caffeic acid, phosphatidyl choline, carnitine, sorivudine, irinotecan, NSAIDs, heterocyclic amines, melamine, nitrazepam, and lovastatin will be reviewed. In addition, recent data that the intestinal microbiota alters drug metabolism of the host, especially Cyp3a, as well as the significance and potential mechanisms of this phenomenon is summarized. The review will conclude with an update of bile acid research, emphasizing the bile acid receptors (FXR and TGR5) that regulate not only bile acid synthesis and transport but also energy metabolism. Recent data indicate that by altering the intestinal microbiota, either by diet or drugs, one may be able to minimize the adverse effects of the Western diet, by altering the composition of bile acids in the intestine that are agonists or antagonists of FXR and TGR5. Therefore, it may be possible to consider the intestinal microbiota as another drug target.
INTRODUCTION

This area of research probably began with studies on bile acids, when it was discovered that bile acids are excreted into bile, metabolized by the intestinal microbiota, and reabsorbed back into the blood to complete what is known as the enterohepatic cycle of bile acids. The intestinal microbiota consists mainly of anaerobic bacteria, which are difficult to culture. This area of research was limited by techniques to quantify numerous microbiota and chemicals rapidly. However, advancements in molecular biology and metabolomics this century resulted in a marked increase of research in this area. By examining the 16S rRNA of bacteria, scientists can determine the genus and species of bacteria. We now know that there are 500-1000 bacterial species in the intestinal microbiota. Over 90 per cent of the intestinal microbiota is composed of the Bacteroides and Firmicutes families. Humans have 10-times more bacterial cells in their intestinal contents than all of the human cells in their bodies, but the bacterial cells are much smaller than human cells. It is said that we are born 100% human, but at death we are 90% bacterial. The amount of bacteria in the lumen of our intestine is two to three pounds, and is about the same size as the brain. The bacterial content of our feces is approximately 60%. Most important for this area of research, are the enzymes that these bacteria synthesize to biotransform chemicals. While the main biotransformation pathway of drugs by humans involves oxidation and conjugation, the major pathways of metabolism by bacteria are reduction and deconjugation. The metabolites of drugs and other xenobiotics formed by the intestinal microbiota may be less or more toxic than
those formed by humans. This review will describe a number of examples of how the intestinal microbiota, by metabolizing chemicals, can decrease or increase the health of the host.

**INTESTINAL MICROBIOTA DELIVERS DRUG TO THE LARGE INTESTINE**

Sulfonamides or sulfa drugs are antibacterial agents that were available before World War 2. Many derivatives of this class of antibiotics have been made, including salicylazosulfapyridine. This drug was synthetized at a time when it was thought that if a single drug combined the biological activity of two drugs, it would produce the effects of both drugs. Thus, salicylazosulfapyridine was a sulfa drug, which has antibiotic activity, and a salicylate, which has anti-inflammatory activity. These two drug moieties were combined with an azo linkage (Figure 1), but are therapeutically effective only after being cleaved.

Salicylazosulfapyridine has been used to treat ulcerative colitis. When administered to rats or humans, the major excretory products was not the parent drug, but rather the two component drugs and their metabolites. Others (Mueller and Miller, 1949; Fouts et al., 1957) had shown that the liver could catalyze the reductive cleavage of certain azo dyes and the sulfonamide prontosil, but the hepatic enzyme activity towards salicylazosulfapyridine was very low. Therefore, studies were done in germ-free rats to determine whether the drug was reduced by the intestinal bacteria. In germ-free animals the parent drug was excreted in the feces, and thus it was concluded that essentially all the reduction was
performed by intestinal bacteria, rather than the liver (Peppercorn and Goldman, 1972b; Goldman et al., 1974). In addition, the oral antibiotic neomycin decreased the reductive cleavage of salicylazosulfapyridine in conventional rats. Because most of the bacteria are localized in the large intestine, the active drug to treat ulcerative colitis was produced precisely where it is needed. One might be able to take advantage of the intestinal microbiota-catalyzed metabolism of prodrugs to deliver to the colon drugs for preventing colon cancer. Sulfasalazine, another drug used in the treatment of ulcerative colitis, Crohn’s disease, and rheumatoid arthritis is poorly absorbed by the gastrointestinal tract, because it is a substrate for the Bcrp (Abcg2) transporter that effluxes chemicals from enterocytes back into the intestinal lumen (Zaher et al., 2006).

**INTESTINAL MICROBIOTA DECREASES DRUG AVAILABLE FOR ABSORPTION, BUT ALTERED BY DIETARY INTERVENTION**

Cardiac glycosides were used as early as the time of the Egyptian and Roman empires and are still used today. Digoxin, which comes from the foxglove plant, is used for the treatment of atrial fibrillation and congestive heart failure. The three sugar molecules of digoxin are not necessary for its pharmacological actions, whereas the unsaturated lactone (a furanone) is about ten times more active than the saturated ring (butyrolactone or dihydrolactone) (Figure 2).

In about 20 percent of people taking digoxin, a substantial amount is excreted with the lactone in the reduced form (dihydrolactone), and stool cultures from
these people produce this same inactive metabolite from digoxin (Lindenbaum et al., 1981). Antibiotics, such as erythromycin and tetracycline, markedly decreased formation of the reduced-lactone metabolite, and increased the serum concentration of the parent drug as much as twofold. Hundreds of human colonic isolates were examined, and it was concluded that *Eubacterium lentum* (now referred to as *Eggerthella lenta*) converted digoxin to the reduced metabolite (Saha et al., 1983). Surprisingly, individuals who did and did not produce the reduced-digoxin metabolite both had similar amounts of *E. lenta* in their intestinal microbiota, and thus the difference must not be due to the number of bacteria but the enzyme activity. When these bacteria were stimulated to grow with arginine, formation of the reduced-lactone of digoxin was diminished.

Thirty years later, using transcription profiling, comparative genomics, and culture-based assays, additional research was conducted to further understand the metabolism of digoxin by *E. lenta*. A cytochrome-encoding operon was identified in *E. lenta*, which is referred to as the “cardiac glycoside reductase” (cgr) operon. The transcription of the cgr operon is induced by digoxin, and its abundance predicts digoxin reduction by the human intestinal microbiota. Germ-free mice did not form dihydromeglocin but when they were colonized with *E. lenta*, they formed the reduced lactone of digoxin. Feeding mice a high-protein diet decreased the formation of dihydromeglocin and increased the serum concentrations of the active form of digoxin (Haiser et al., 2013).
INTESTINAL MICROBIOTA DECREASES ABSORPTION OF DRUG BY METABOLIZING AND POSSIBLY BINDING THE DRUG

Levodopa or L-dopa (L-3,4-dihydroxyphenylalanine) is used for the treatment of Parkinson’s disease, which is a neurodegenerative disease characterized by four major clinical features: tremor, bradykinesia, rigidity, and disturbance of posture. Parkinson’s disease is the result of degeneration of the dopamine neurons in the basal ganglia. Therefore a major treatment of Parkinson’s disease is to increase dopamine levels in the basal ganglia. Because dopamine does not pass the blood-brain barrier, L-dopa is given and is decarboxylated by an amino acid decarboxylase in the brain to produce dopamine.

In the late 1960’s, it was shown that the levels of m-hydroxyphenylacetic acid in patients being treated with L-dopa decreased markedly when they were given the antibiotic, neomycin (Sandler et al., 1969) (Figure 3). In fact, it was concluded the p-dehydroxylation of L-dopa to m-hydroxyphenylacetic acid was catalyzed entirely by intestinal microbiota. Similarly in rats, neomycin decreases the p-dehydroxylation of L-dopa to m-hydroxyphenylacetic acid (Bakke, 1971), and germ-free rats treated with L-dopa do not form m-hydroxyphenylacetic acid.

Marshall and Warren received a Nobel Prize in 2005 for their discovery that inflammation in the stomach (gastritis) as well as ulceration of the stomach or duodenum (peptic-ulcer disease) is the result of infection of the stomach by the bacterium *Helicobacter pylori*. A number of clinicians have also noted an
association of Parkinson’s disease and *H. pylori* infection. A clinical pharmacokinetic study was performed in Parkinson disease patients, and when the patients were pre-treated with antibiotics to treat the *H. pylori* (amoxicillin, clarithromycin, and omeprazole) higher blood levels of L-dopa were observed than in patients not treated with the antibiotics (Pierantozzi et al., 2006). Subsequently, an *in vitro* study demonstrated that L-dopa can bind to *H. pylori* and the authors suggested that this might be the reason for the lower absorption of L-dopa in Parkinson’s patients infected with *H. pylori*.

**INTESTINAL MICROBIOTA INCREASES AVAILABILITY OF DRUG BECAUSE MICROBIOTA PRODUCE A CHEMICAL THAT COMPETES WITH DRUG FOR DETOXICATION BY THE HOST**

Acetaminophen is one of the most used non-prescription drugs in the world. It is an analgesic and antipyretic, but with overdose produces liver injury, and if severe, may require liver transplantation. The importance of biotransformation of acetaminophen in producing hepatotoxicity has been known since the early 1970s (Mitchell et al., 1973; Klaassen et al., 2013). Acetaminophen undergoes sulfation and glucuronidation, which are mediated by phase-II enzymes that conjugate the hydroxyl group of the drug with a sulfate or glucuronic acid, which detoxifies acetaminophen and enhances its excretion. These phase-II or conjugation reactions require not only an enzyme for the reaction, but also the co-substrate: 3’-phosphoadenosine-5’-phosphosulfate (PAPS) for sulfation and UDP-glucuronic acid for glucuronidation. Sulfation and glucuronidation of
acetaminophen occurs in both the intestinal mucosa and liver, and both pathways are limited, apparently due to depletion of the co-substrates (Hjelle and Klaassen, 1984; Hjelle et al., 1985; Goon and Klaassen, 1990; Boles and Klaassen, 2000). A small portion of acetaminophen (less than 10%) is activated by the cytochrome P-450 enzymes (CYP2E1, 1A2, and 3A4) to a reactive electrophile (N-acetyl-p-benzoquinoneimine (NAPQI), which is detoxified by conjugation with glutathione. However, when glutathione levels are depleted, the reactive metabolites bind to macromolecules in hepatocytes, resulting in liver necrosis.

In an attempt to find biomarkers that might be used in personalized health care, a metabolomic analysis of chemicals in urine of people was quantified before and after a dose of acetaminophen. As anticipated, the major acetaminophen metabolites detected in urine were the sulfate and glucuronide conjugates; however, there were marked differences in the sulfate/glucuronide acetaminophen metabolite ratios among the various subjects. It was also noted that the people who excreted less acetaminophen-sulfate in urine had more cresol-sulfate in their urine before acetaminophen administration. Cresol-sulfate in urine originates from tyrosine, one of the amino acids in dietary proteins (Figure 4). Tyrosine is metabolized by the intestinal microbiota to cresol (p-hydroxytoluene), which is then sulfated by the intestine and liver before excretion into urine. Therefore, it has been proposed that cresol and acetaminophen compete for sulfation by enterocytes, and thus the more cresol formed by the
microbiota, the less acetaminophen is sulfated and detoxified (Clayton et al., 2009).

**INTESTINAL MICROBIOTA BIOTRANSFORM COMMON FOOD CONSTITUENTS**

Caffeic acid (3,4-dihydroxycinnamic acid) is a dietary constituent found in all plants, due to its key role in the biosynthesis of lignin, an integral part of plant cell walls. Caffeic acid is found in very high levels (140 mg/100 g) in black chokecherry, and high levels (20 mg/100 g) are present in herbs, especially thyme, sage, and spearmint, as well as in some spices such as Ceylon cinnamon.

Caffeic acid is biotransformed to more than 10 metabolites found in the urine of rats and humans, with dihydrocaffeic acid and m-hydroxyphenylproprionic acid being the primary metabolites formed, which can be further biotransformed by methylation and other reactions (Booth et al., 1957) (Figure 5). By administration of neomycin to suppress the intestinal microbiota (Dayman and Jepson, 1969) or utilizing germ-free rats (Peppercorn and Goldman, 1972a). It was discovered that the reduction and dehydroxylation reactions were performed by the intestinal microbiota. More recently, the biotransformation of caffeic acid in chlorogenic acid, which is an ester of caffeic acid and quinic acid, is also largely dependent on the intestinal microbiota (Gonthier et al., 2003).
INTESTINAL MICROBIOTA BIOTRANSFORMS TRYPTOPHAN INTO AhR RECEPTOR AGONISTS THAT STIMULATE THE IMMUNE SYSTEM TO MAINTAIN A HEALTHY INTESTINE

TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) is the most potent agonist of the aryl-hydrocarbon receptor (AhR) and an immunotoxicant (Holsapple et al., 1991; Kerkvliet, 2002). However, more recent data indicates that with less activation of the AhR, the receptor plays an important physiological role in the immune system (Stockinger et al., 2011). The physiological activator of the AhR in the gastrointestinal tract appears to be a metabolite of the amino acid tryptophan, as a diet lacking in tryptophan impairs intestinal immunity in mice and alters the microbial community (Hashimoto et al., 2012). By correlating changes in tryptophan catabolic profiles with microbiota metagenomic composition, it was concluded that indole-3-aldehyde might be the AhR ligand important for intestinal immunity (Zelante et al., 2013). When the AhR is activated in lymphoid cells, they release IL-22, which in turn induces the synthesis of lipocalin-2 and calprotectin by the host. These two proteins sequester essential metal ions (iron, zinc, and manganese) that reduces their availability to bacteria, which results in the inhibition and growth of opportunistic bacteria (Behnsen and Raffatellu, 2013).

INTESTINAL MICROBIOTA BIOTRANSFORMS FOOD CONSTITUENTS INTO CHEMICALS THAT PROMOTE CARDIOVASCULAR DISEASE
Cardiovascular disease is a leading cause of death and morbidity. In an attempt to determine pathways and/or a biomarker for cardiovascular disease, a metabolomics study of small molecules in the plasma was performed. Three chemicals in the blood, namely choline, trimethylamine N-oxide (TMAO), and betaine (N,N,N-trimethylglycine), all which are metabolites of phosphatidylcholine, were shown to predict cardiovascular disease in a large clinical cohort (Wang et al., 2011). Phosphatidylcholine (also called lecithin) is a major component of biological membranes, and foods rich in phosphatidylcholine include eggs, milk, liver, red meat, chicken, shell fish, fish, and soybeans. Choline has a number of functions in the body; it is a component of the neurotransmitter acetylcholine, and betaine, a cofactor for one-carbon metabolism.

When mice were fed a diet supplemented with TMAO, an upregulation of multiple macrophage scavenger receptors linked to atherosclerosis was observed, as well as increased accumulation of lipids in macrophages, and atherosclerosis. However, in mice receiving antibiotics or in germ-free mice, the TMAO did not produce atherosclerotic lesions (Wang et al., 2011). Similarly in humans, plasma concentrations of TMAO were suppressed markedly after administration of antibiotics and then rebounded after withdrawal of the antibiotics (Tang et al., 2013). The anaerobic conversion of choline to trimethylamine (TMA) in sulfate-reducing bacteria is catalyzed by enzymes encoded by genes in the so-called choline utilization cluster (Cut). One of the genes in this cluster encodes the glycyl radical enzyme (GRE) choline TMA lyase (CutC), which converts choline...
to TMA by a glycyl radical reaction (Craciun and Balskus, 2012). TMA is a volatile compound with an ammonia-like odor. While the intestinal microbiota are responsible for the formation of trimethylamine from choline, the flavin mono-oxygenases (FMOs) in the liver of the host are responsible for N-oxidation of TMA to TMA-N-oxide (TMAO). Some humans have a defective FMO, and may develop “fish-odor syndrome”.

Carnitine is abundant in red meats, and is biologically important for the transport of long-chain fatty acids into mitochondria for their breakdown by β-oxidation in the generation of ATP. Carnitine has a quaternary nitrogen, similar to choline, and as described for choline, carnitine is catabolized by the intestinal microbiota to TMA, which is oxidized to TMAO by FMO in the liver of the host (Figure 7).

Supplementation of the diets of mice with carnitine markedly enhanced the concentration of TMA and TMAO in the plasma as well as atherosclerosis, but not in mice in which the intestinal microbiota were suppressed by antibiotics. Mice fed a diet enriched with carnitine, choline, or TMAO had reduced cholesterol transport in vivo. They also showed that humans convert carnitine to TMAO, and humans who eat carnivorous diets produce more TMAO than humans who consume vegetarian/vegan diets (Koeth et al., 2013).
INTESTINAL MICROBIOTA FORMS A DRUG METABOLITE THAT INACTIVATES A HOST ENZYME THAT BIOTRANSFORMS A SECOND DRUG

In 1993, a drug-drug interaction resulted in the death of eighteen Japanese cancer patients with herpes zoster, a viral disease, following treatment with a new antiviral drug Sorivudine, in addition to an anticancer prodrug of 5-fluorouracil (5-FU), namely tegafur or capecitabine, which are biotransformed to 5-FU. These deaths occurred within 40 days after sorivudine was approved for clinical use.

5-FU and its prodrugs are known to have toxic effects to various tissues that have rapid cell proliferation, especially the intestinal mucosa and bone marrow. As a result, patients receiving high doses of 5-FU often experience diarrhea and decreases in white blood cells and platelets. The patients who died also experienced these signs and symptoms, suggesting that the toxicity was due to increased concentrations of 5-FU reaching the systemic circulation. 5-FU is detoxified by dihydropyrimidine dehydrogenase, the same enzyme that metabolizes the endogenous pyrimidines, uracil and thymine.

Sorivudine and 5-FU were given to rats and essentially identical drug-drug interactions were observed in rats as in humans, namely diarrhea, marked decrease in white blood cells and platelets, and death within 10 days (Okuda et al., 1997). However, Sorivudine did not inhibit in vitro either rat or human
DMD # 65698

dihydropyrimidine dehydrogenase (Ogura et al., 1998). It had been
demonstrated a decade earlier that bromovinyluracil was a potent inhibitor of
dihydropyrimidine dehydrogenase and that it would increase the biological half-
life of 5-FU five-fold and increase the area under the curve (AUC) by 8-fold in rats (Desgranges et al., 1986). In patients, sorivudine also decreased
dihydropyrimidine dehydrogenase enzyme activity and it took four weeks to
return to normal (Yan et al., 1997).

There was minimal or no enzymatic activity in liver, kidney, or intestines of rats to
convert sorivudine to the bromovinyluracil metabolite, but the enzyme activity to
produce the metabolite was high in the intestinal contents (Nakayama et al.,
1997) (Figure 8). When antibiotics were given to rats that also were receiving
sorivudine, very little bromovinyluracil was detected in the blood, in contrast to
rats not receiving the antibiotics to decrease the intestinal microbiota. The
metabolism of bromovinyluracil by dihydropyrimidine dehydrogenase (in the host)
produces a reactive intermediate that irreversibly inhibits the enzyme, a process
called suicide inhibition or mechanism-based enzyme inactivation (Nishiyama et
al., 2000). When bromovinyluracil formed from Surividine by intestinal microbiota
inactivates dihydropyrimidine dehydrogenase, 5-FU is not detoxified.
Consequently, the metabolism of Sorivudine by intestinal microbiota played a key
role in the deaths of patients prescribed both Sorivudine and 5-FU prodrugs.
INTESTINAL MICROBIOTA RESPONSIBLE FOR INTESTINAL TOXICITY OF CANCER CHEMOTHERAPEUTIC DRUG

Irinotecan is a common chemotherapeutic drug for colorectal cancer. The dose-limiting toxicities are neutropenia and late-onset diarrhea. The diarrhea is often sufficiently severe to require hospitalizations, and dose reduction, which can lead to ineffective treatment. Irinotecan is biotransformed by carboxylesterase of the host to produce SN-38, the active form of the drug. SN-38 is detoxified in the host by glucuronidation (Figure 9).

In a study with rats, it was noted that the toxicity of irinotecan to various segments of the intestine was not correlated with intestinal tissue carboxylase activity, but rather with the β-glucuronidase activity of the contents in the lumen of the various segments. When antibiotics were given orally to rats to diminish their intestinal microbiota, the antibiotics completely inhibited the conversion of SN-38 glucuronide back to SN-38, and there was a marked amelioration of the diarrhea as well as reduced intestinal injury (Takasuna et al., 1996). In addition, irinotecan increases β-glucuronidase containing bacteria in the intestine of rats, further increasing the potential of conversion of SN-38 glucuronide back to the active and toxic metabolite SN-38 (Stringer et al., 2008). Inhibitors of bacterial β-glucuronidase also protected mice against the intestinal toxicity of irinotecan (Wallace et al., 2010). Thus the intestinal toxicity of irinotecan is due to the release of SN-38 in the colon following deconjugation of SN-38-glucuronide by the intestinal microbiota. Thus either an inhibitor of intestinal β-glucuronidase or an
antibiotic has the clinical potential to decrease irinotecan-induced intestinal toxicity.

**INTESTINAL MICROBIOTA INCREASES THE DURATION OF DRUG ACTION AND INCREASES DRUG TOXICITY**

There are many endogenous chemicals as well as drugs and other xenobiotics that are glucuronidated before being excreted into bile. A few examples include the sex hormones, thyroxine, morphine, cardiac glycosides, indomethacin, naphthol, propofol, and oxazepam. Once the drugs are glucuronidated by the intestine and/or the liver, they are often transported into the bile and excreted into the intestine. As noted for irinotecan, many glucuronidated chemicals can be de-conjugated by intestinal bacteria that express the β-glucuronidase gene. Thus when the drug glucuronide is hydrolyzed by intestinal microbiota, the parent drug can be reabsorbed into the systemic circulation and increase the duration of action of the drug.

It has been known for more than a half century that the enterohepatic circulation of drugs might be advantageous for the pharmacological effects of some drugs as it will prolong the action of the drug, but it is not desirable when a patient has developed toxicity from one of these drugs. For example, digitoxin has a very small margin of safety (a narrow therapeutic index), meaning that the difference between the blood concentrations of digitoxin that produces the desired effects on the heart and the blood concentration that produces toxicity is quite small.
When the blood concentration of digitoxin reaches a toxic level, it would be advantageous to inhibit the enterohepatic circulation of digitoxin. Cholestyramine, an anion-binding resin prescribed for the treatment of hypercholesterolemia, will also bind digitoxin and interfere with its enterohepatic circulation and decrease the toxic blood concentration to a safe-pharmacological concentration (Caldwell et al., 1971).

**INTESTINAL MICROBIOTA RESPONSIBLE FOR DRUG-INDUCED INTESTINAL TOXICITY**

Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammation, pain, and fever. Inflammation is a normal process in response to infections, as well as physical or chemical injury. The ability to mount an inflammatory response is essential to deal with pathogens and injury, however the inflammatory response can be exaggerated and prolonged, apparently without benefit and with severe adverse consequences. The pharmacological actions of the NSAIDs are due to their ability to inhibit prostaglandin synthase enzymes, commonly known as the cyclooxygenases (COXs). Inhibition of COX-2 is considered responsible for producing the desired effects of NSAIDs, whereas inhibition of COX-1 is largely responsible for a major undesirable effect, GI irritation and ulcers.

Many carboxylic acid-containing NSAIDs are conjugated with glucuronic acid in the liver before being transported into bile and excreted into the intestine (Figure
10). In one study, mice were given the NSAID diclofenac at a dose that produces numerous large ulcers in the distal section of the small intestine. In a second group of mice, a bacteria-specific $\beta$-glucuronidase inhibitor was administered concurrently with the same dose of diclofenac, and this second group of mice had much less intestinal mucosal injury (LoGuidice et al., 2012). Similar studies have been done with two additional NSAIDs, indomethacin and ketoprofen, and again the intestinal lesions were reduced by an inhibitor of bacterial $\beta$-glucuronidase (Saitta et al., 2014). These data suggest the intestinal lesions produced by the NSAIDs are due to the $\beta$-glucuronidase in the intestinal microbiota that release the aglycone that is then free to enter the enterocytes to produce its toxic effects. Inhibition of $\beta$-glucuronidase of the intestinal microbiota prevents the formation of the aglycone, and thus affords protection from NSAID-induced intestinal toxicity.

**INTESTINAL MICROBIOTA DECREASES AND INCREASES THE MUTAGENICITY OF FOOD-PYROLYSIS PRODUCTS**

Heterocyclic amines are formed during high-temperature cooking of meat and fish (food rich in protein, creatinine, and carbohydrates. Normally in such heating, desirable flavor compounds are formed, however heterocyclic amines are also formed. Many heterocyclic amines are carcinogens.

There are more than 20 heterocyclic amines formed in high-temperature cooking of food. Noted above is the structure of 2-amino-3-methylimidazo[4,5f]quinolone
and 2-amino-1-methyl-6-phenylimidazo(4,5b)pyridine, more commonly known as IQ and PhIP (Figure 11). Other heterocyclic amines in food are MeIQ, Me1Qx, Glu-P-1, Glu-P-2, Trp-P-1, and Trp-P-2. These chemicals are mutagenic in the Ames test, and have been shown to be carcinogenic in rodent feeding studies. While tumors are produced in many tissues, the most common is liver tumors. The carcinogenic properties of the heterocyclic amines are due to their metabolites, formed by $N$-hydroxylation by the cytochrome P450 enzymes, followed by $O$-sulfation and $O$-acetylation that results in reactive products that bind to DNA (Klaassen, 2013).

An *in vitro* study showed that a number of these food-derived heterocyclic amines can bind to both gram-positive and gram-negative bacteria. Studies with *Lactobacillus casei* indicated that the binding was pH dependent (Morotomi and Mutai, 1986), and an additional study demonstrated that PhIP, a major mutagenic heterocyclic amine in the Western diet, bound better to lactic-acid producing strains than the other heterocyclic amines (Orrhage et al., 1994). A number of epidemiology and laboratory animal studies have shown that the consumption of cultured dairy products, such as yogurt, decreases the incidence of cancer. The lactic-acid producing bacteria in yogurt are usually *Lactobacillus* or *Bifidobacterium*. Therefore rats were fed a 5% diet of lyophilized cultures of *Bifidobacterium*, as well as 125 ppm IQ in the diet for 58 weeks. It was found that the *Bifidobacterium* in the diet inhibited IQ-induced colon and liver tumors in rats (Reddy and Rivenson, 1993). To determine whether the intestinal microbiota
would also protect against heterocyclic amines, germ-free mice were inoculated
with human fecal suspension. IQ was given to both germ-free mice as well as the
humanized-microbiota mice and binding of IQ in various tissues of the two
groups of mice were quantified. Fewer DNA adducts of IQ were observed in the
humanized-microbiota mice than in germ-free mice, indicating that both murine
and human-microbiota are able to protect against IQ genotoxicity (Hirayama et
al., 2000).

In contrast to the previous studies indicating that some bacteria can protect
against food-derived heterocyclic amines, more recently, a study has been
published indicating that other intestinal bacteria increase the genotoxicity of
these chemicals. In this study, germ-free rats were inoculated with either an
Escherichia coli strain that contains the uidA gene that codes for β-
glucuronidase, or with an identical strain that does not contain the uidA gene.
The bacteria that expressed β-glucuronidase increased the genotoxicity of IQ in
the intestine 3-fold over the rats that were inoculated with the bacteria that did
not express β-glucuronidase (Humblot et al., 2007). Thus, it has been proposed
that glucuronidation of heterocyclic amines by the host decreases their
mutagenicity, but the β-glucuronidase in the intestinal microbiota hydrolyze the
glucuronide and release the toxic heterocyclic amine.
INTESTINAL MICROBIOTA METABOLIZES SUBSTRATE THAT CO-CRYSTALLIZES WITH THE SUBSTRATE AND PRECIPITATES IN KIDNEY TUBULES TO PRODUCE TOXICITY

In 2007 both household pets and children were poisoned by melamine as it was added to cat and dog food as well as milk in China. The melamine was added to increase the apparent protein concentration of the food. The contaminated pet food was consumed by many cats and dogs in North America. The melamine in the pet food and milk resulted in acute kidney toxicity in cats, dogs, and humans. Pathological evaluation of cats and dogs that had died indicated the presence of crystals in the kidney tubules. HPLC-MS/MS analysis identified melamine and cyanuric acid in the kidney, and microspectroscopy confirmed the presence of melamine-cyanuric acid co-crystals (Dobson et al., 2008) (Figure 12). Thus the renal toxicity of two rather innocuous compounds resulted from their co-crystalizations, forming an insoluble precipitate in renal tubules leading to progressive tubular blockage and degeneration.

More recently, melamine was given to conventional rats and to rats that had their intestinal-microbiota suppressed by antibiotics. The renal toxicity of melamine was attenuated and melamine excretion was increased in the intestinal-microbiota suppressed rats. It was also shown that normal rat feces can biotransform melamine to cyanuric acid. *Klebsiella terrigena* was shown to directly convert melamine to cyanuric acid, and rats inoculated with these bacteria showed exacerbated melamine-induced nephrotoxicity (Zheng et al.,
Therefore melamine-induced nephrotoxicity is dependent on the composition and metabolic activity of the intestinal microbiota.

**INTESTINAL MICROBIOTA METABOLIZES DRUG TO A TERATOGEN**

Nitrazepam is a benzodiazepine drug that is used for short-term relief of severe anxiety and insomnia. Nitrazepam is a teratogen when administered to pregnant rats, resulting in exencephaly, cleft palate, limb reductions, and other external and skeletal malformations. Incubation of nitrazepam with bacterial suspensions from rat cecal contents resulted in extensive reduction to 7-aminonitrazepam (Figure 13). Antibiotic treatment of the pregnant rats prior to nitrazepam resulted in decreased production of the reduced compound from 30 to 2% of the dose. The incidence of nitrazepam-induced malformations was also markedly reduced by the antibiotic treatment. This suggests that the intestinal microflora reduces nitrazepam to 7-aminonitrazepam, which is responsible for the teratogenicity (Takeno et al., 1990; Takeno and Sakai, 1991).

**INTESTINAL MICROBIOTA CONVERTS PRODRUG TO AN ACTIVE DRUG**

Lovastatin is a hypolipidemic drug used to lower cholesterol. The mechanism of action of all statin drugs is to inhibit the enzyme HMG-CoA reductase, which converts HMG-CoA to mevalonate. Lovastatin is a prodrug, which needs to be converted from the gamma-lactone closed ring to the β-hydroxy acid open ring form to be active (Figure 14). Incubation of lovastatin with bacteria from rat and human feces produced the active hydroxy-acid metabolite. When lovastatin was
given to rats after their intestinal microbiota was markedly decreased by antibiotics, the hydroxy-acid metabolite was decreased about 50% in the plasma. These results indicate that antibiotics given to patients can result in drug-drug interactions by altering the intestinal microbiota (Yoo et al., 2014).

**INTESTINAL MICROBIOTA BIOTRANSFORMS ADDITIONAL DRUGS AND XENOBIOTICS**

Table 1 indicates a number of chemicals that are biotransformed by the intestinal microbiota, the type of chemical reaction, as well as the function of the drug or chemical. Many biotransformations by the intestinal microbiota do not have marked pharmacological or toxicological effects on the host. There are numerous reasons for this. A major reason is that most drugs are absorbed in the small intestine, but most of the microbiota is in the large intestine. Therefore, the microbiota is likely to have greater effects on poorly-absorbed drugs and drugs that are designed to be delayed release. The effect is also dependent on the fraction of the drug that is biotransformed by the intestinal microbiota as well as the nature of the metabolite formed.

**INTESTINAL MICROBIOTA AFFECTS HOST DRUG METABOLISM**

Very few studies have been published on the effect of intestinal microbiota on drug disposition by the host. However, it is well known that some Phase-I enzymes (oxidation, reduction, and hydrolysis enzymes), Phase-II enzymes,
DMD # 65698

(conjugation enzymes), and transporters (both uptake and efflux transporters) are inducible and inhibited by drugs and other chemicals. Therefore, chemicals normally produced by the intestinal flora might likewise induce or inhibit drug metabolizing enzymes and transporters (Klaassen, 2013).

Comparisons of the expression of the mRNAs of these drug-processing genes in conventional and germ-free mice have been reported (Bjorkholm et al., 2009; Toda et al., 2009; Selwyn et al., 2015). Quantification of the mRNA in conventional and germ-free mice indicate that 21 drug-processing genes were increased and 34 were decreased by the germ-free condition. Probably the most important findings are that the level of mRNA encoding Cyp3a in the germ-free mice is much lower, and the level of mRNA encoding Cyp4a is much higher in livers of germ-free mice (Selwyn et al., 2015) (Figure 14).

The reason why the decrease in Cyp3a is of such importance is because it metabolizes over 50% of drugs, and the quantity of mRNA decreased markedly (87%) in the germ-free mice. In addition to mRNA content, the levels of Cyp3a11 protein also decreased markedly (Selwyn et al., 2015). The mechanism for the marked reduction of Cyp3a11 is not known, but Cyp3a11 is a well-known target gene of the PXR transcription factor. Because there is less Cyp3a11 in germ-free mice, this could indicate that the intestinal microbiota normally produces a ligand for PXR, and thus in the germ-free mice there may be less activation of PXR. One possible PXR ligand in conventional mice that is not present in germ-
free mice is lithocholic acid. Lithocholic acid is a secondary bile acid produced from chenodeoxycholic acid by the intestinal microbiota, and lithocholic acid has been shown to be a PXR activator (Staudinger et al., 2001). Another possibility is an intestinal-microbiota metabolite of tryptophan, namely indole-3-propionic acid, which is formed by Clostridium sporgenes (Wikoff et al., 2009) (Figure 16) and is a PXR ligand (Venkatesh et al., 2014). In humans there are marked inter-individual differences in the expression of CYP3A4, and it is possible that these differences are due in part to variation in the intestinal microbiota in humans.

The Cyp4 subfamily of Cyp enzymes is not as important for biotransforming drugs and other xenobiotics as are the Cyp1, 2, and 3 families. The Cyp4 enzymes are mainly involved in the metabolism of fatty acids and eicosanoids, and their mRNA and protein expression are regulated by the PPARα nuclear receptor. Because Cyp4a14 is regulated by PPARα, the increase in Cyp4a14 mRNA observed in germ-free mice might be a consequence of the absence of intestinal bacteria that catabolize chemicals that otherwise activates PPARα. It is known that PPARα is activated by lipids, as well as numerous drugs and other chemicals, such as the hypolipidemic fibrate drugs (clofibrate), NSAIDs, organic solvents (trichloroacetic acid), phthalate ester plasticizers, herbicides (2,4-dichlorophenoxyacetic acid), and perfluorodecanoic acid. At the present time it is not known what chemical, if any, is responsible for the activation of PPARα in germ-free mice, and the ultimate answer will require further studies to determine the mechanism for the increase in Cyp4a in germ-free mice.
COMPOSITION OF THE INTESTINAL MICROBIOTA

The intestinal microbiota is thought to consist of 500 to 1000 species of bacteria. More than 90% of the species are Firmicutes and Bacteroidetes (Table 2). The various bacteria have numerous functions, but an essential function is energy harvest. Carbohydrates are important sources of energy for both host and bacteria. However, the host cannot degrade most complex carbohydrates and polysaccharides. These non-digestible carbohydrates are fermented in the colon by its microbiota to yield short-chain fatty acids, mainly acetate, propionate, and butyrate. Butyrate is an energy source for the colonic epithelium, whereas acetate and propionate are used by the peripheral tissues of the host. The types and amounts of short-chain fatty acids produced are determined by the amount of carbohydrate consumed and the composition of the gut microbiota. The short-chain fatty acids are an energy source for certain bacteria and the intestinal epithelial cells, and are also important for intestinal morphology and function. The short-chain fatty acids produce their effects by binding to endogenous receptors GPR41 and GPR43. A diet rich in fiber increases the proportion of Bacteroidaceae and Bifidobacteriaceae, whereas a low-fiber diet leads to microbiota that are dominated by Firmicutes, particularly those of the Erysipelotrichaceae family (Trompette et al., 2014). Thus there is a symbiotic relationship between the intestinal microbiota and the host. Furthermore the intestinal microbiota provides the host with vitamin B-complex and vitamin K.
INTESTINAL MICROBIOTA AND OBESITY

In an attempt to determine whether the intestinal microbiota could play a role in the obesity epidemic, a high-fat, high-sugar (Western) diet was provided to germ-free and conventional mice. Surprisingly, the germ-free mice were protected from the obesity, insulin resistance, and hypercholesterolemia of the Western diet (Backhed et al., 2007; Rabot et al., 2010). The results of this landmark study stimulated further research on the interactions of diet, intestinal microbiota, and obesity.

The intestinal microbiota of lean and obese mice littermates, as well as from lean and obese humans differ in the proportion of Bacteroidetes and Firmicutes, with the obese mice and humans having an increase in Firmicutes (Turnbaugh et al., 2008; 2009). A similar change in the intestinal microbiota of mice was observed when mice were fed a high-fat and high-sugar (Western) diet in comparison to mice fed a low-fat and high-polysaccharide diet, with the Western diet increasing the Firmicutes and decreasing the Bacteroides, with a marked increase in Mollicutes, such as *Eubacterium dolichum* (Turnbaugh et al., 2008). When ‘obese microbiota’ was transferred from obese mice to germ-free mice, the mice gained more weight than the mice that obtained the ‘lean microbiota’ (Turnbaugh et al., 2006).

In a recent study, the microbiota from lean and obese twins were given to germ-free mice. The mice given the ‘obese microbiota’ resulted in larger body weight
and adiposity, increased metabolism of branched-chain amino acids, decreased fermentation of short-chain fatty acids, and changes in bile acid species with an accompanying decrease in intestinal FXR signaling. Cohousing the lean and obese mice transformed the intestinal microbiota of obese mice towards an intestinal microbiota more similar to that of lean mice (Ridaura et al., 2013). Diet is the dominate factor influencing the composition of the intestinal microbiota (Carmody et al., 2015). Numerous studies have shown that switching mice from a control to a high-fat (Western) diet will result in an increased Firmicutes/Bacteroidetes ratio in their intestinal microbiota and the mice will exhibit metabolic syndrome, such as obesity, insulin resistance, dyslipidemia, and non-alcoholic steatohepatitis (NASH). This change in the intestinal microbiota by changing the diet can occur within a single day (Turnbaugh et al., 2009). Recently it has been shown that there is even a circadian rhythm in the intestinal microbiota of mice (Zarrinpar et al., 2014).

**PREBIOTICS AND PROBIOTICS ALTER THE INTESTINAL MICROBIOTA**

For various perceived health benefits, and because there is a correlation between the types of bacteria in the intestine and signs of metabolic-syndrome, attempts have been made to alter the human intestinal microbiota by the use of probiotics and prebiotics. Probiotics are live microorganisms that, when consumed confer a health benefit to the host. *Lactobacillus* and *Bifidobacterium* are the most common strains used as probiotics. In contrast, prebiotics are non-digestible food ingredients that selectively stimulate the growth of some
beneficial bacteria, Inulin and *trans*-galacto-oligosacharide stimulate the growth of *Bifidobacterium*, and thus is known as a bifidogenic effect (Tremaroli and Backhed, 2012). Studies performed in both mice and humans using live organisms (probiotics) or fermentable carbohydrates (prebiotics) have demonstrated positive effects in altering obesity, hyperglycemia, and hepatic steatosis (Druart et al., 2014). Additional research is needed to determine the “dose response” of prebiotics and probiotics required to elicit desirable effects, undesirable effects, and the mechanism of both the desirable and undesirable effects of prebiotics and probiotics.

**BILE ACIDS AND THE INTESTINAL MICROBIOTA**

Bile acids are toxic to microbiota. Bile acids are also metabolized by intestinal microbiota, which has consequences for the bacteria (decreased toxicity) and the host (altered homeostasis). Therefore, bile acid synthesis, transport, and regulation will be reviewed with emphasis on the role of intestinal microbiota.

Bile acids are synthesized in the liver from cholesterol. As depicted if Figure 17, there are two pathways in the synthesis of bile acids, the classical and alternative pathway. The rate-limiting step in the synthesis of bile acids is catalyzed by Cyp7a1. The bile acids synthesized in liver are referred to as primary bile acids. The two primary bile acids synthesized by humans are cholic acid (CA) and chenodeoxycholic acid (CDCA). Mice also produce these two primary bile acids, but in addition also synthesize α- and β-muricholic acid (MCA). Before excretion
Into bile, they are conjugated with glycine or taurine in humans, and in mice, primarily taurine (Figure 17).

In the intestine, the microbiota biotransform the primary bile acids synthesized in the liver into secondary bile acids. The conjugated bile acids excreted into bile are partially deconjugated, partially 7-dehydroxylated, and partially reduced/epimerized by the intestinal microbiota, which markedly increases the diversity of bile acids. The bile acids return to the liver, where some of the secondary bile acids can be biotransformed back into primary bile acids, for example by 7-hydroxylation of deoxycholic acid to cholic acid (in mice), and re-conjugating the bile acids that were deconjugated by the intestinal microbiota (Figure 18).

Humans have about eight grams of bile acids in their bodies, mainly in the liver and intestinal tract. Only about five percent of the bile acids are excreted in the feces each day. If a person eats three meals a day, the bile acids are excreted into and reabsorbed from the intestine at least three times a day, which suggests that at least 98% of the bile acids undergo enterohepatic circulation. This efficient system requires bile acid transporters in both the liver and intestine (Figure 19). The bile acids in the liver are transported into the bile canaliculi by the bile salt export pump (Bsep), in the intestine they are transported into enterocytes by the apical sodium bile acid transporter (Asbt), and effluxed out of the enterocytes by the heterodimer organic solute transporter α and β (Ostα/Ostβ). The bile acids
then are delivered to the liver by the portal vein, where the hepatocytes have two transporters for the uptake of bile acids, one for the unconjugated bile acids, the organic anion transporting polypeptide 1b2 (Oatp1b2), and another for conjugated bile acids, the sodium taurocholate cotransporting polypeptide (Ntcp) (Klaassen and Aleksunes, 2010; Csanaky et al., 2011) (Figure 19).

The intestinal microbiota is responsible for the conversion of primary bile acids synthesized in the liver to secondary bile acids in the intestine. The removal of taurine and glycine from conjugated bile acids is performed by the enzyme bile salt hydrolase (BSH), which is widespread in the intestinal microbiota. Deconjugation provides carbon, nitrogen, and sulfur for some bacteria. Unlike glycine, taurine contains a sulfonic acid moiety that is further catabolized to carbon disulfide. The 3-, 7-, and 12- hydroxyl groups of bile acids synthesized by livers are all in the alpha configuration, which results in the hydroxyl-groups on one side of the steroid molecule and none on the other side making the bile acids excellent detergents to aid in the solubilization and absorption of lipids and lipid-soluble vitamins. However, the intestinal bacteria can oxidize and epimerize the α-OH bile acids to β-OH bile acids and visa versa. The reason why bacteria convert α- to β-OH bile acids, is probably to decrease the toxicity of the bile acid to the bacteria. The epimerization requires the formation of a stable oxo-bile acid intermediate, and thus the formation of the β-OH bile acid requires the combined effort of two specific hydroxysteroid dehydrogenases (HSDHs). Many Clostridia and a few other bacteria are known to perform these reactions. Deoxycholic and
lithocholic acid are the two predominant bile acids in human feces; thus 7-dehydroxylation is an extremely common bile acid biotransformation reaction. The $7\alpha/\beta$-dehydroxylation pathway requires multiple oxidative and reductive steps with a net two-electron reduction, and thus an energy benefit for the bacteria, however more toxic secondary bile acids are formed (Ridlon et al., 2006). Thus as a result of the host and the intestinal microbiota, a large diversity of bile acids is produced.

**BILE ACIDS REGULATE THE INTESTINAL MICROBIOTA**

Bile acids are also a regulator of the intestinal microbiota. It has been known since the 1940s that bile acids have antimicrobial properties (Stacey and Webb, 1947). Most studies on the antimicrobial properties of bile acids have been done *in vitro*. However, a recent study in which rats were fed a diet containing cholic acid resulted in a marked decrease in Bacteroidetes from 37% to almost none, and an increase in Firmicutes from 54 to 95% of the intestinal microbiota. Within the Firmicutes phylum, an increase in *Clostridium* and *Ruminococcus* occurred, which are $7\alpha$-dehydroxylating bacteria, resulted in an increased rate of conversion of cholic acid to deoxycholic acid (Islam et al., 2011), which is a better antimicrobial agent than cholic acid (Begley et al., 2005). Thus bile acids convert the intestinal microbiota to a higher Firmicutes/Bacteroidetes ratio, similar to what is observed after a high-fat diet.

**BILE ACIDS AS SIGNALING MOLECULES**
Until recently, it was thought that the function of bile acids was two-fold. One is to enhance the absorption of lipids and lipid soluble vitamins from the gastrointestinal tract, and the other is their secretion across the canaliculi to generate bile flow. At the turn of this century, it was discovered that there is a bile acid receptor in the liver, named the farnesoid-X-receptor (FXR) (Goodwin et al., 2000). This receptor appeared to be very important for the regulation of bile acid synthesis in the liver (I in Figure 20). It was later discovered that the intestine also expresses FXR, which regulates the secretion of fibroblast growth factor 15 (Fgf15). Fgf15 is delivered by the portal blood to the liver where it also regulates BA synthesis (II in Figure 20) (Inagaki et al., 2005; Kim et al., 2007; Kong et al., 2012). The FXR receptor not only effects bile acid synthesis but also carbohydrate metabolism (Cariou et al., 2005; Duran-Sandoval et al., 2005; Ma et al., 2006) and inflammation (Gadaleta et al., 2011).

The second major bile acid receptor is a G protein-coupled receptor (GPCR) that has been named TGR5 and is important in the regulation of energy metabolism (Watanabe et al., 2006). In contrast to FXR that is an intracellular receptor, TGR5 is a cell-surface bile acid receptor. As shown in Figure 20, TGR5 has at least three important functions (III-A, III-B, and III-C). IIIA illustrates that TGR5 is located in the intestine, and bile acids can promote glucagon-like peptide-1 (GLP1) secretion upon activation by bile acids (Katsuma et al., 2005; Thomas et al., 2009). Patients treated with a bile acid-binding resin to reduce cholesterol levels also have improved glycemic control, and bile acid-binding resins also
improve hyperglycemia in rodent models of obesity (Kobayashi et al., 2007; Chen et al., 2010) possibly because resins provide more bile acids to the lower intestine to activate TGR5. TGR5-overexpressing mice have enhanced GLP-1 secretion and insulin release in response to a glucose load, and TGR5-null mice have impaired glucose tolerance (Thomas et al., 2009). TGR5 activation by bile acids regulates energy expenditure and glucose homeostasis (Watanabe et al., 2006). Thus, through TGR5, bile acids regulate GLP-1 and subsequently regulate glucose homeostasis. A second function of TGR5, noted as III-B in Figure 20, is its effects on the gall bladder and bile duct. In the gallbladder, TGR5 agonists increase cAMP levels and decrease intracellular chloride concentrations by increasing chloride secretion via the cAMP-regulated chloride channel, which is the cystic fibrosis trans-membrane and conductance regulator (CFTR) (Keitel et al., 2009). TGR5-null mice have reduced gallbladder size. The TGR5 agonist INT-777 (a bile acid analog) increases gallbladder filling and gallbladder size in control mice but not in TGR5-null mice, illustrating that TGR5 activation promotes smooth muscle relaxation in gallbladder, leading to gallbladder filling. The third site where TGR5 has a major function is muscle and brown fat, as depicted in III-C in Figure 20. Bile acids bind to TGR5 expressed in brown adipose tissue and skeletal muscle, and increase intracellular cAMP, which in turn increases type-2 iodothyronine-deiodinase (D2) activity. This enzyme is a thyroid hormone activating enzyme, that converts T4 to T3, which up-regulates uncoupling proteins 1 and 3 (Ucp1 and Ucp3), and increases energy expenditure as heat (Watanabe et al., 2006). Treating diet-induced...
obese mice with the TGR5 agonist INT-777, leads to reduced body weight gain and increased energy expenditure in brown-adipose tissue by up-regulating the expression of mRNA for D2 deiodinase, Ucp1, and Ucp3 (Thomas et al., 2009). Therefore, activation of TGR5 influences energy expenditure in skeletal muscle and brown-adipose tissue. Both bile acid receptors (FXR and TGR5) appear to be receptors that might be important in treating metabolic syndrome (Li and Chiang, 2014; Li and Chiang, 2015).

**BILE ACIDS, INTESTINAL MICROBIOTA, AND METABOLIC SYNDROME**

When mice are switched from a control to a high-fat diet, they gain considerable weight. However, when germ-free mice are placed on a high-fat diet, they don’t exhibit such a marked increase in body weight (Backhed et al., 2007; Ding et al., 2010; Rabot et al., 2010). Germ-free mice also have higher bile acid concentrations in their plasma and liver than conventional mice. Mice fed antibiotics also have higher bile acid levels (Miyata et al., 2009; Zhang et al., 2014), as do Cyp8b1-null (12α-hydroxylase-null) mice. These three condition increased concentrations of tauro-β-muricholic acid (the taurine conjugate of β-muricholic acid) which acts as an antagonist of the FXR receptor, thus decreasing Fgf15, which decreases Cyp7a1, the enzyme that catalyzes the rate-limiting step of bile acid synthesis in the liver (Sayin et al., 2013; Hu et al., 2014). Thus, some bile acids are FXR agonists and others are antagonists. It has been shown recently that Cyp8b1-null mice have improved glucose homeostasis due to elevated levels of GLP-1 (Kaur et al., 2015) which increases the biosynthesis
and secretion of insulin by pancreatic beta cells, leading to improved glucose
tolerance in Cyp8b1-null mice. This effect of GLP-1 is most likely due to the
ability of various bile acids to activate the TGR-5 receptor. Unfortunately, at the
present time there is little or no information on which bile acids are agonists and
antagonists of either the FXR or TGR-5 receptor in vivo. However, both receptors
appear to be drug targets that could improve human health.

EFFECT OF A CHEMICAL ON INTESTINAL MICROBIOTA, BILE ACIDS, AND
METABOLIC SYNDROME

Tempol, an antioxidant and radiation protector, prevents obesity in mice. To
determine the mechanism of this phenomenon, a metabolomic analysis of
chemicals in the intestine and feces of control and tempol-treated mice was
investigated. A major difference between the two groups of mice was a marked
increase in tauro-β-muricholic acid in the intestine of the tempol-treated mice.
The tempol-treated mice have an altered intestinal microbiota with an increase in
Bacteroidetes and decrease in Firmicutes. More specifically there was a marked
decrease in Lactobacillus which is a bile salt hydroxylase producing bacteria.
Thus, in the mice treated with tempol, there is more tauro-β-muricholic acid,
which is a FXR antagonist. Therefore less FGF15, an inhibitor of bile acid
synthesis, is secreted by the ileum to reach the liver, and thus Cyp7a1 is not
inhibited, and more bile acids are synthesized. Because FXR is not only involved
in regulating bile acid synthesis, but also in glucose metabolism, these data
suggest that FXR could be a target for anti-obesity drugs (Li et al., 2013).
EFFECT OF ENVIRONMENTAL CHEMICALS ON INTESTINAL MICROBIOTA

The aryl hydrocarbon receptor (AhR) is a xenobiotic receptor that can be activated by numerous chemicals, such as the environmental pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polychlorinated biphenyls, and halogenated aromatic hydrocarbons. The toxicity of many of these chemicals appears to be due to binding and activating the AhR. As noted previously, tryptophan catabolites produced by the intestinal microbiota can also activate the AhR receptor. Recently, a persistent environmental contaminant, 2,3,7,8-tetrachlorodibenzofuran (TCDF), an AhR agonist, was given to mice and a marked increase in inflammation in the intestine and bile acids in the liver were detected. This was accompanied by an increase in Bacteroides and decrease in Firmicutes in the intestinal microbiota, more specifically an enrichment of Butyrivibrio and a depletion of Oscillobacter. This was accompanied by a decrease in FXR signaling. The authors concluded that the TCDF altered the intestinal microbiota, which modulated the nuclear receptor signaling of FXR, and subsequently altered metabolism of the host (Zhang et al., 2015).

In addition to organic chemicals, metals are also able to alter the intestinal microbiota. Germ-free and conventional mice were given cadmium or lead in their drinking water. Much more cadmium and lead were found in the tissues of the germ-free mice; thus the microbiota were protective for cadmium and lead (Breton et al., 2013). The mechanism for this protection is not known. Arsenic
also perturbs the gut microbiota and its metabolomic profile. Mice were exposed to arsenic in the drinking water (10 ppm) for four weeks. The Bacteroidetes were not altered, but four Firmicutes families were decreased (Lu et al., 2014). A high-fat (Western) diet fed to mice will produce non-alcoholic hepatic steatosis (NASH), and the addition of arsenic to the water of mice fed a high-fat diet enhances the liver injury, which is characterized by enhanced inflammation (Tan et al., 2011). Feeding the prebiotic oligofructose, protected mice against the enhanced liver damage caused by arsenic in the presence of a high-fat diet. These results indicate that prebiotics can protect against some toxicities (Massey et al., 2015).

SUMMARY AND CONCLUSION

In this review, we have attempted to review the various effects of the intestinal microbiota on the biotransformation of drugs and other chemicals. As noted, the intestinal microbiota can deliver a drug to the large intestine, and it can also be responsible for the toxic effect of a chemical. Numerous examples have been given to demonstrate the mechanism by which the intestinal microbiota produces these toxic effects. However, as noted throughout the text, by understanding and altering the intestinal microbiota one can decrease the toxicity of a number of chemicals. Also by altering the intestinal microbiota one may be able to minimize the metabolic syndrome, which includes obesity, diabetes, atherosclerosis, fatty liver, and liver cancer. Thus, one can consider the intestinal microbiota as another drug target.
ACKNOWLEDGEMENTS

The authors thank Andrew and Oliver Parkinson for proof-reading this review, and Dr. Feng Li for drawing the chemical structures.

AUTHOR CONTRIBUTIONS

Wrote or contributed to the writing of the manuscript: Curtis Klaassen, Julia Yue Cui
REFERENCES


DMD # 65698


DMD # 65698


dehydrogenase by (E)-5-(2-bromovinyl)uracil in the presence of NADPH.

Mol Pharmacol 57:899-905.


Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, and Ware JA (2006) Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of


FIGURE LEGENDS

Figure 1. Metabolism of salicylazosulfapyridine.

Figure 2. Metabolism of digoxin.

Figure 3. Metabolism of L-dopa.

Figure 4. Sulfation of acetaminophen and cresol.

Figure 5. Metabolism of caffeic acid

Figure 6. Metabolism of phosphatidylcholine.

Figure 7. Chemical structures of choline and carnitine.

Figure 8. Metabolism of sorivudine.

Figure 9. Metabolism of irinotecan.

Figure 10. Metabolism of diclofenac.

Figure 11. Chemical structures of PhIP and IQ.

Figure 12. Chemical structures of melamine and cyanuric acid.

Figure 13. Metabolism of nitrazepam.

Figure 14. Metabolism of lovastatin.

Figure 15. Messenger RNA of Cyp3a11 and Cyp4a14 in conventional and germ-free mice.

Figure 16. Metabolism of tryptophan.

Figure 17. Synthesis and metabolism of bile acids.

Figure 18. Chemical structures of bile acids.

Figure 19. Uptake and efflux transporters of bile acids.
Figure 20. Schematic diagram of (I) FXR receptor in liver, (II) FXR receptor in intestine, (IIIA) TGR5 receptor in intestine, (IIIB) TGR5 receptor in gallbladder, and (IIIC) TGR5 receptor in fat and muscle.
# TABLE 1. Chemicals Biotransformed by Intestinal Microbiome

Other

<table>
<thead>
<tr>
<th>Bacterial biotransformation</th>
<th>Chemicals</th>
<th>Chemical applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azoreduction</td>
<td>Prontosil</td>
<td>anti-bacterial</td>
</tr>
<tr>
<td></td>
<td>Neoprontosil</td>
<td>anti-bacterial</td>
</tr>
<tr>
<td></td>
<td>Sulfasalazine</td>
<td>anti-bacterial</td>
</tr>
<tr>
<td></td>
<td>Balsalazide</td>
<td>anti-bacterial</td>
</tr>
<tr>
<td></td>
<td>Olsalazine</td>
<td>anti-inflammatory</td>
</tr>
<tr>
<td>Reduction</td>
<td>Nitrazepam</td>
<td>anti-anxiety</td>
</tr>
<tr>
<td></td>
<td>Clonazepam</td>
<td>anti-anxiety</td>
</tr>
<tr>
<td></td>
<td>Misonidazole</td>
<td>radiation sensitizer</td>
</tr>
<tr>
<td></td>
<td>Omeprazole</td>
<td>anti-heartburn and anti-ulcer</td>
</tr>
<tr>
<td></td>
<td>Sulfinpyrazone</td>
<td>uricosuric</td>
</tr>
<tr>
<td></td>
<td>Sulindac</td>
<td>anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>Digoxin</td>
<td>anti-fibrillation</td>
</tr>
<tr>
<td></td>
<td>Zonisamide</td>
<td>anti-convulsant</td>
</tr>
<tr>
<td></td>
<td>Metronidazole</td>
<td>anti-bacterial</td>
</tr>
<tr>
<td>Hydrolysis</td>
<td>Lactulose</td>
<td>anti-constipation</td>
</tr>
<tr>
<td></td>
<td>Sorivudine</td>
<td>anti-viral</td>
</tr>
<tr>
<td>Succinate group removal</td>
<td>Succinylsulfathiazole</td>
<td>anti-bacterial</td>
</tr>
<tr>
<td>Dehydroxylation</td>
<td>Levo-Dopa</td>
<td>anti-Parkinsons</td>
</tr>
<tr>
<td>Acetylation</td>
<td>5-Aminosalicylic acid</td>
<td>anti-inflammatory</td>
</tr>
<tr>
<td>Deacetylation</td>
<td>Phenacetin</td>
<td>analgesic and antipyretic</td>
</tr>
<tr>
<td>(N)-oxide bond bond cleavage</td>
<td>Ranitidine</td>
<td>anti-heartburn and anti-ulcer</td>
</tr>
<tr>
<td></td>
<td>Nizatidine</td>
<td>anti-heartburn and anti-ulcer</td>
</tr>
<tr>
<td>Proteolysis</td>
<td>Insulin</td>
<td>decrease blood glucose</td>
</tr>
<tr>
<td></td>
<td>Calcitonin</td>
<td>decrease blood calcium</td>
</tr>
<tr>
<td>Denitration</td>
<td>Glyceryl trinitrate</td>
<td>anti-angena</td>
</tr>
<tr>
<td></td>
<td>Isosorbide dinitrate</td>
<td>anti-angena</td>
</tr>
<tr>
<td>Amine formation and hydrolysis of amide bond</td>
<td>Chloramphenicol</td>
<td>antibiotic</td>
</tr>
<tr>
<td>Deconjugation</td>
<td>Digitoxin</td>
<td>anti-fibrillation</td>
</tr>
<tr>
<td></td>
<td>Indomethacin</td>
<td>anti-inflammatory</td>
</tr>
<tr>
<td>Chemical Reactions</td>
<td>Examples</td>
<td>Description</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Estrogens</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bile acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiazole ring opening</td>
<td>Levamisole</td>
<td>anthelmic</td>
</tr>
<tr>
<td>Isoxazole scission</td>
<td>Risperidone</td>
<td>anti-psychotic</td>
</tr>
<tr>
<td>Deglycosylation</td>
<td>Quercetin-3-glucoside</td>
<td>natural product</td>
</tr>
<tr>
<td>N-demethylation</td>
<td>Methamphetamine</td>
<td>CNS stimulant</td>
</tr>
<tr>
<td>Other chemical reactions</td>
<td>Azetirelin, Potassium oxonate, Flucytosine, Hesperidin, Daidzein</td>
<td>increases thyrotropin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>part of anti-tumor drug</td>
</tr>
<tr>
<td></td>
<td></td>
<td>anti-fungal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>natural product</td>
</tr>
<tr>
<td></td>
<td></td>
<td>natural product</td>
</tr>
</tbody>
</table>

Based on Sousa et al., 2008 18,682,282
### TABLE 2

<table>
<thead>
<tr>
<th>Intestinal microbiota</th>
<th>Strains</th>
</tr>
</thead>
</table>
| **Firmicutes** (Gram-positive) | Acetitomaculum spp.  
Allisonella spp.  
Anaerofustis spp.  
Anaerotruncus spp.  
Anaerococcus sp.  
Bulleidia spp.  
Catenibacterium spp.  
Clostridium spp.  
Coprococcus spp.  
Dialister spp.  
Dorea spp.  
Enterococcus spp.  
Erysipelotrichus  
Eubacterium spp.  
Faecalibacterium spp.  
Gemella spp.  
Lactobacillus spp.  
Lachnospira spp.  
Peptococcus spp.  
Peptostreptococcus spp.  
Roseburia spp.  
Ruminococcus spp.  
Staphylococcus spp.  
Subdoligranulum spp. |
| **Actinobacteria** (Gram-positive) | Actinomyces spp.  
Bifidobacterium spp.  
Collinsella spp.  
Corynebacterium spp. |
| **Bacteroidetes** (Gram-negative) | Alistipes spp.  
Bacteroides spp.  
Porphyromonas gingivalis  
Prevotella spp.  
Rikenellaceae family  
Xylanibacter spp. |
<p>| <strong>Fusobacteria</strong> (Gram-negative) | Fusobacterium spp |</p>
<table>
<thead>
<tr>
<th>Domain</th>
<th>Phyllum</th>
<th>Class</th>
<th>Genus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proteobacteria</strong> (Gram-negative)</td>
<td></td>
<td><strong>Bilophilia wadsworthii</strong></td>
<td><strong>Desulfovibrio piger</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Enterobactericeae family</strong></td>
<td><strong>Escherichia coli</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Haemophilus parainfluenzae</strong></td>
</tr>
<tr>
<td><strong>Veillonellae</strong> (Gram-negative)</td>
<td></td>
<td><strong>Veillonella spp.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Verrucomicrobia</strong></td>
<td></td>
<td></td>
<td><strong>Akkermansia spp.</strong></td>
</tr>
<tr>
<td><strong>Archeae</strong></td>
<td></td>
<td></td>
<td><strong>Euryarchaeota spp.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Methanobrevibacter spp.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Methanosphaera spp.</strong></td>
</tr>
</tbody>
</table>
Figure 1

Sulfasalazine

Azoreductase

5-Aminosalicylic acid  
Sulfapyridine
Figure 2

Digoxin → Cardiac glycoside reductase → Dihydrdigoxin
Figure 3

Levodopa → Amino acid decarboxylase → Dopamine

\[ \text{Levodopa} \xrightarrow{\text{\(p\)-Dehydroxylation}} \xrightarrow{\text{Decarboxylation}} \text{\(m\)-Tyramine} \]
Figure 4

Acetaminophen \[\rightarrow\] Acetaminophen sulfate

Tyrosine \[\rightarrow\] p-Cresol \[\rightarrow\] p-Cresol sulfate
Figure 5

Caffeic acid

Reduction

Dihydrocaffeic acid

p-Dehydroxylation

m-Hydroxyphenylpropanoic acid
Figure 7

Choline

\[
\begin{align*}
\text{HO}-\text{C}-\text{C}-\text{N}-\text{CH}_3 \\
\text{H}-\text{H}-\text{CH}_3
\end{align*}
\]

Carnitine

\[
\begin{align*}
\text{HO}-\text{C}-\text{C}-\text{C}-\text{N}-\text{CH}_3 \\
\text{O}-\text{H}-\text{OH}-\text{H}-\text{CH}_3
\end{align*}
\]
Figure 8

Sorivudine → Bromovinyluracil
Figure 10

![Chemical structures of Diclofenac and its glucuronide metabolite.](image-url)
Figure 11

PhIP

IQ
Figure 12

Melamine

Cyanuric acid

Melamine cyanurate
Figure 13

The diagram shows the chemical structures of Nitrazepam and 7-Aminonitrazepam. Nitrazepam undergoes reduction to form 7-Aminonitrazepam.
Figure 14

Lovastatin

Ring opening

Chemical structure of Lovastatin after ring opening.
Figure 17

Classical Pathway

Cholesterol → Cyp7a1 → Cyp8b1 → CA → T-CA

Alternative Pathway

Cholesterol → Cyp27a1 → Cyp7b1 → CDCA → α,β-MCA → T-α,β-MCA → Bacteria in Intestine

Bacteria in Intestine → DCA, UDCA, LCA, ωMCA, HDCA, MDCA

Liver

Bacteria in Intestine → T-DCA, T-UDCA, T-LCA, T-ωMCA, T-HDCA, T-MDCA
Figure 18

Chemical structures of the most important BAs in humans and rodents.

<table>
<thead>
<tr>
<th>Bile acids</th>
<th>Abbrev.</th>
<th>3α</th>
<th>3β</th>
<th>6α</th>
<th>6β</th>
<th>7α</th>
<th>7β</th>
<th>12α</th>
<th>12β</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary bile acids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cholic acid</td>
<td>CA</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
<td>OH</td>
<td>H</td>
</tr>
<tr>
<td>chenodeoxycholic acid</td>
<td>CDCA</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>α-muricholic acid</td>
<td>αMCA</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>β-muricholic acid</td>
<td>βMCA</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
<td>OH</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>Secondary bile acids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>deoxycholic acid</td>
<td>DCA</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
</tr>
<tr>
<td>lithocholic acid</td>
<td>LCA</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>ω-muricholic acid</td>
<td>ωMCA</td>
<td>OH</td>
<td>H</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>OH</td>
<td>H</td>
<td>H</td>
</tr>
</tbody>
</table>